By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile



Meibergdreef 61

  Amsterdam  1105 BA  Netherlands
Phone: 31-20-566-7394 Fax: 31-20-566-9272



Company News
uniQure (QURE) Announces Financial Results For Second Quarter 2016 And Update On Company Progress 8/26/2016 8:32:21 AM
uniQure (QURE) To Present At Upcoming Investor Conferences In September 8/17/2016 9:09:16 AM
Shire (SHPG) Kills Baxalta (BXLT)'s Hemophilia B Program; Clears Path for BioMarin (BMRN), Spark Therapeutics (ONCE) and uniQure (QURE) 8/3/2016 7:26:00 AM
uniQure (QURE) Presents Updated Clinical Data In Patients With Severe Hemophilia B Demonstrating Up To 9 Months Of Sustained Levels Of Factor IX Activity And Therapeutic Effect 7/28/2016 8:09:13 AM
uniQure (QURE) Announces Oral Presentation Of Updated Results For AMT-060 At The World Federation Of Hemophilia (WFH) 2016 World Congress 7/11/2016 12:51:10 PM
uniQure (QURE) Appoints Jonathan Garen As Chief Business Officer 7/7/2016 8:38:14 AM
Protein Sciences Corporation Announces Exclusive License To uniQure (QURE) Of Cell Line And Technology For Production Of Human Gene Therapies 6/28/2016 10:07:50 AM
uniQure (QURE) Appoints Maria E. Cantor As Senior Vice President, Investor Relations & Communications 6/27/2016 9:53:43 AM
uniQure (QURE) Presents Clinical Data From Ongoing Phase I/II Study In Hemophilia B Demonstrating 6 Months Of Sustained Increases In Factor IX Activity 6/13/2016 7:46:59 AM
uniQure (QURE) Announces Results For First Quarter 2016 5/31/2016 10:32:25 AM